Jul 16, 2024 8:00am EDT Algernon Pharmaceuticals Reports Results of Study Showing 93% Cough Suppression with Ifenprodil
May 21, 2024 7:00am EDT Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services
Apr 24, 2024 7:47am EDT Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
Apr 11, 2024 7:00am EDT Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024
Apr 01, 2024 7:00am EDT Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset
Mar 27, 2024 12:04pm EDT Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
Jan 31, 2024 7:00am EST Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD
Jan 11, 2024 7:00am EST Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis
